This page brings together the European Medicines Agency's (EMA) latest information on diabetes. It lists:
Semglee is a medicine used to treat diabetes in patients from 2 years of age. It contains the active substance insulin glargine. Semglee is a ‘biosimilar medicine’. This means that Semglee is highly...
Kirsty is a medicine used to control blood glucose (sugar) levels in patients from one year of age who have diabetes. Kirsty is a ‘biosimilar medicine’. This means that Kirsty is highly similar to...
This is a summary of the European public assessment report (EPAR) for Xelevia. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in...
Toujeo is a medicine used to control blood glucose (sugar) levels in adults and children from 6 years of age who have diabetes and need insulin. It contains the active substance insulin glargine.
This is a summary of the European public assessment report (EPAR) for Velmetia. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in...
PRAC recommends measures to minimise the risk of serious side effects with medicines containing pseudoephedrine EMA’s safety committee, PRAC, has recommended new measures for medicines containing pseudoephedrine to minimise the risks of posterior...
GLP-1 receptor agonists: available evidence not supporting link with thyroid cancer EMA’s safety committee (PRAC) has concluded that the available evidence does not support a causal association between the Glucagon-Like Peptide-1 Receptor Agonists (...
New safety information for Omega-3-acid ethyl esters The PRAC agreed to add atrial fibrillation (irregular, rapid contraction of the heart) as a common side effect to the product information for medicines containing omega-3-acid ethyl esters. These...
Four new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended granting a marketing authorisation for Sotyktu (deucravacitinib) for the treatment of moderate to severe plaque psoriasis in adults, a skin disease...
Five new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended five medicines for approval at its December 2022 meeting. The CHMP recommended granting a conditional marketing authorisation for the advanced therapy...
Nine new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended nine medicines for approval at its May 2022 meeting. A recommendation for marketing authorisation was adopted for Cevenfacta (eptacog beta (activated))...